Pharsight

Rexulti generic

Rexulti is an anti-psychotic drug owned by Otsuka. It contains the active ingredient brexpiprazole and was first authorized for market use on July 10, 2015. Rexulti holds a total of 6 drug patents, none of which have expired yet. The drug is available in tablet form for oral administration.

When will Rexulti generic be available?

The Rexulti generic is projected to become available after October 12, 2032, following the expiration of the drug's last patent (US10307419) titled 'Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof'.

Rexulti uses

Rexulti is primarily used for the treatment of schizophrenia in adults and pediatric patients aged 13 years and older. It is also used as an adjunctive treatment for major depressive disorder (MDD). The effectiveness of Rexulti stems from its active ingredient, brexpiprazole, which works to balance out the neurotransmitters in the brain.

Rexulti patent expiration

Rexulti holds a total of 6 patents. The last patent, holding the title 'Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof' with the patent number US10307419, is set to expire on October 12, 2032, paving the way for the debut of Rexulti generic alternatives. Below is the detail of the patent:

EPO Oppostions filed on Rexulti

Rexulti dosage

Want to ask something?